Related Experiment Videos
Progressive Supranuclear Palsy.
1Department of Neurology, UMDNJ Robert Wood Johnson Medical School, 97 Paterson Street, New Brunswick, NJ 08901, USA. golbe@umdnj.edu
Current Treatment Options in Neurology
|October 3, 2001
Summary
Currently, no drug effectively treats progressive supranuclear palsy (PSP). Future treatments may focus on mitochondrial energy, neurotrophic factors, tau aggregation, or splicing regulation.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with limited therapeutic options.
- Current treatments offer only modest or transient benefits.
- The complex pathology involving multiple neuronal systems complicates drug development.
Purpose of the Study:
- To review the current state of drug treatment for progressive supranuclear palsy (PSP).
- To explore potential future therapeutic strategies for PSP.
- To outline the role of neurologists in managing PSP patients.
Main Methods:
- Literature review of existing and emerging treatments for PSP.
- Analysis of the pathophysiological basis of PSP to identify therapeutic targets.
- Discussion of clinical management strategies for PSP complications.
Main Results:
- No current drug provides substantial or lasting benefit for PSP.
- Neurotransmitter-specific approaches are unlikely to be effective due to disease complexity.
- Potential future therapies include mitochondrial enhancers, neurotrophic factor inducers, tau aggregation inhibitors, and alternative splicing regulators.
Conclusions:
- Effective pharmacological treatments for PSP are currently lacking.
- Future research should focus on novel therapeutic avenues targeting fundamental disease mechanisms.
- Neurologists play a crucial role in providing supportive care, prognostic guidance, and managing complications like aspiration and falls in PSP patients.